Demographic, clinical, and laboratory characteristics of the studied population.
| No PTE (N=132) | PTE (N=99) | ||
|---|---|---|---|
| Age (yr), mean (SD) | 58.0 (17.9) | 59.0 (17.6) | 0.665 |
| Gender-male, N (%) | 63 (47.7) | 68 (68.7) | 0.001a) |
| Comorbidities, N (%) | |||
| Diabetes mellitus | 22 (16.7) | 19 (19.2) | 0.619 |
| Chronic obstructive pulmonary disease | 8 (6.1) | 2 (2.0) | 0.135 |
| End-stage renal disease | 0 (0) | 3 (3.0) | - |
| Malignancy | 3 (3.0) | 3 (3.0) | 1.000 |
| Cerebrovascular accident | 7 (5.3) | 6 (6.1) | 0.805 |
| Ischemic heart disease | 15 (11.4) | 20 (20.2) | 0.064 |
| Previous history of pulmonary thromboembolism | 1 (0.76) | 1 (1.0) | 0.838 |
| Having the least of one comorbidity | 48 (36.4) | 38 (38.4) | 0.753 |
| Current smoking, N (%) | 10 (7.6) | 12 (12.1) | 0.244 |
| History of medications, N/N (%) | |||
| None | 31/103 (30.1) | 66/94 (70.2) | <0.0001a) |
| Aspirin | 13/102 (12.8) | 20/94 (21.3) | 0.111 |
| Clopidogrel | 0/131 (0) | 1/99 (1.0) | 0.249 |
| Anticoagulant prophylaxis | 2/132 (1.52) | 3/99 (3.0) | 0.434 |
| Therapeutic anticoagulant | 0/132 (0) | 2/99 (2.0) | 0.156 |
| On admission clinical presentations | |||
| Systolic blood pressure, mean (SD) | 127.1 (23.6) | 124.1 (17.8) | 0.297 |
| Systolic blood pressure <90 mmHg, N (%) | 3 (2.3) | 1 (1.0) | 0.637 |
| Diastolic blood pressure, mean (SD) | 77.8 (15.8) | 78.8 (13.1) | 0.624 |
| Diastolic blood pressure <60 mmHg, N (%) | 3 (2.3) | 1 (1.0) | 0.637 |
| Pulse rate per minute, mean (SD) | 92.3 (18.6) | 94.7 (18.0) | 0.332 |
| Pulse rate >100 per minute, N (%) | 33 (25.0) | 33 (33.3) | 0.165 |
| Respiratory rate per minute-mean (SD) | 24.5 (6.4) | 24.6 (5.7) | 0.838 |
| Respiratory rate >30 per minute, N (%) | 15 (11.4) | 13 (13.1) | 0.684 |
| O2 saturation (%), mean (SD) | 86.1 (8.2) | 81.8 (10.9) | 0.001a) |
| O2 saturation t <90%, N (%) | 83 (62.9) | 79 (79.8) | 0.005a) |
| O2 saturation 90–93%, N(%) | 25 (18.9) | 9 (9.1) | 0.037a) |
| O2 saturation >93%, N(%) | 24 (18.2) | 11 (11.1) | 0.138 |
| Clinical presentations three days before CT-scan, N (%) | |||
| Relative bed rest | 75 (56.8) | 34 (40.5) | 0.019a) |
| Complete bed rest | 77 (58.3) | 63 (75.0) | 0.012a) |
| On admission laboratory characteristics, mean (SD) | |||
| Neutrophil count (per mL) | 6,042 (4,100) | 7,851 (4,016) | 0.001a) |
| Lymphocyte count (per mL) | 1,239 (1,015) | 1,048 (1,016) | 0.161 |
| Platelet ×103 (per mL) | 193.9 (95.7) | 216.3 (94.4) | 0.905 |
| Neutrophil-to-lymphocyte ratio | 6.9 (6.9) | 10.3 (8.1) | 0.001a) |
| International normalized ratio | 1.23 (0.56) | 1.27 (0.43) | 0.544 |
| Hemoglobin (mg/dL) | 13.3 (1.9) | 12.6 (2.3) | 0.006a) |
| Ferritin (μg/L) | 814.7 (582.5) | 817.2 (554.7) | 0.978 |
| Fibrinogen degradation products (μg/mL) | 25.8 (8.9) | 26.2 (5.8) | 0.871 |
| Fibrinogen (mg/dL) | 331.7 (111.4) | 278.3(106.5) | 0.040a) |
| Prothrombin time (s) | 13.8 (5.5) | 14.1 (4.4) | 0.721 |
| Partial thromboplastin time (s) | 37.2 (15.7) | 32.4 (8.2) | 0.010a) |
| Albumin (g/dL) | 3.64 (0.63) | 3.25 (0.52) | <0.0001a) |
| Troponin (ng/mL) | 68.2 (232.8) | 230.0 (495.1) | 0.019a) |
| D-dimer (μg/mL) | 2,869 (3,285) | 4,775 (3,641) | 0.001a) |
| C-reactive protein (mg/L) | 67.6 (46.3) | 85.2 (45.4) | 0.006a) |
| Lactate dehydrogenase (IU/L) | 794.2 (385.1) | 1,016.6 (527.4) | 0.001a) |
| Maximum laboratory characteristics-Median (IQR) | |||
| D-dimer (μg/mL) | 1,971 (817–4,732) | 3,550 (2,259–8,191) | <0.0001a) |
| C-reactive protein (mg/L) | 77 (54–111) | 98 (60–125) | 0.034a) |
| Lactate dehydrogenase (IU/L) | 803 (629–1,215) | 1,020 (683–1,380) | 0.017a) |
| Maximum increase compared to admission time, mean (min–max) | |||
| D-dimer (μg/mL) | 575.9 (0–8,909) | 359.7 (0–9,363) | 0.050 |
| C-reactive protein (mg/L) | 11.0 (0–102) | 5.0 (0–86) | 0.032a) |
| Lactate dehydrogenase (IU/L) | 188.6 (0–2,242) | 114.3 (0–2,644) | 0.206 |
a)Chi2/exact test for categorical variable, independent T-test or Wilcoxon rank-sum test for continuous variable were significant if
Abbreviation: PTE, pulmonary thromboembolism.
Blood Res 2021;56:293~300 https://doi.org/10.5045/br.2021.2021131
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd